HOME >> BIOLOGY >> NEWS
Marimastat produces comparable survival rates to chemotherapy in some advanced pancreatic cancer patients

Marimastat, a matrix metalloproteinase inhibitor, offers a similar survival benefit to chemotherapy in patients with non-metastatic pancreatic cancer, but with fewer side effects, reports an international team of researchers from the United States and Britain.

The randomized clinical trial compared the effects of three different doses of marimastat with the chemotherapy drug gemcitabine in 414 patients with advanced pancreatic cancer. During this clinical trial, gemcitabine was approved for use in pancreatic cancer, and is now considered the standard of care.

According to the study, the one-year survival rate for patients with localized cancer was 20 percent for patients given the highest dose of marimastat and 19 percent for patients treated with gemcitabine. Although patients taking gemcitabine reported greater improvements in pain and mood, fewer toxic side effects (e.g., pulmonary complications and nausea) were reported in patients taking marimastat versus gemcitabine (12 percent versus 22 percent, respectively).

Marimastat did not show benefit in lower doses or in patients with metastatic pancreatic cancer. The one-year survival rate for patients taking lower doses of marimastat was 14 percent.

Researchers say marimastat appears to benefit some non-metastatic patients and suggest the agent be tested in those patients in combination with gemcitabine. "Five years ago, patients with advanced pancreatic cancer did not have any good treatment options, but gemcitabine and newly engineered drugs like marimastat are giving us hope," says the study leader Simon Bramhall, from the Queen Elizabeth Hospital, Birmingham, England. "These clinical trial results are encouraging and suggest that targeted molecular therapy may benefit some patients."

Matrix metalloproteinase inhibitors restrict the growth and spread of solid tumors by blocking blood vessel growth to the site of tumors. Marimastat is also being tested in ovarian a
'"/>

Contact: Carrie Bittman
bittmanc@asco.org
703-299-1016
American Society of Clinical Oncology
30-Jul-2001


Page: 1 2

Related biology news :

1. Genetic modification of linseed produces healthier omega 3 and 6 fatty acids
2. Spontaneous mutation produces new MAO A/B knockout mouse
3. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
4. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
5. First genetic comparison of purebred domestic dogs produces surprises
6. Biological computer diagnoses cancer and produces drug in a test tube
7. High-fat fast-food breakfast produces rush of inflammatory factors into blood stream, UB study finds
8. Oil exploitation in Ecuadors Amazon basin produces a public health emergency
9. Method produces uniform, self-assembled nanocells
10. Scientists develop plant that produces potential anti-carcinogen
11. Brains master molecule produces same behavior in mice from three different psychostimulant drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2019)... ... October 11, 2019 , ... Advanced Clinical, a clinical ... Pavel Tyan has been appointed Therapeutic Lead for Oncology. Dr. Tyan brings a ... already strong scientific and delivery credentials previously offered at Advanced Clinical. , Dr. ...
(Date:10/8/2019)... ... October 08, 2019 , ... Enplug , a ... easier than ever for businesses and organizations to use their digital signage networks ... to count down to or count up from date-related milestones, while the Holidays ...
(Date:10/3/2019)... ... October 01, 2019 , ... The ... of chemicals, reagents, and medias and to be a more environmentally sustainable evolution ... culmination of years of experience and feedback from the original version we launched ...
Breaking Biology News(10 mins):
(Date:10/10/2019)... ... October 09, 2019 , ... ... Montgomery County middle school and high school students have improved neuro-cognitive executive skills ... techniques and physical fitness, and apply lifelong social/interpersonal, leadership, problem-solving and coping skills, ...
(Date:10/8/2019)... ... October 08, 2019 , ... Today, Massachusetts stem cell biotechnology company ... technology. Like the company’s precursor patent, approved in the U.S. in 2017, the ... stem cells. Asymmetrex now markets the technology in the U.S. as the AlphaSTEM ...
(Date:10/3/2019)... ... October 02, 2019 , ... eKare’s inSight® digital 3D ... Health Accelerator run by the East Midlands Academic Health Science Network (EMAHSN), the innovation ... technology in NHS by providing support to develop and deploy solutions to the most ...
(Date:9/24/2019)... ... September 24, 2019 , ... Drug resistance has been declared as one of ... MRSA becoming one of the most serious concerns. Hong Kong cannot be spared from ... MRSA (CA-MRSA), or a seven-fold of the figure in 2007 – the year the ...
Breaking Biology Technology:
Cached News: